Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Accumulated Depreciation (2017 - 2025)

Sutro Biopharma's Accumulated Depreciation history spans 6 years, with the latest figure at $48.6 million for Q4 2024.

  • For Q4 2024, Accumulated Depreciation changed N/A year-over-year to $48.6 million; the TTM value through Dec 2024 reached $48.6 million, changed N/A, while the annual FY2024 figure was $48.6 million, N/A changed from the prior year.
  • Accumulated Depreciation for Q4 2024 was $48.6 million at Sutro Biopharma, up from $33.4 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $48.6 million in Q4 2024 and bottomed at $33.4 million in Q4 2021.
  • The 3-year median for Accumulated Depreciation is $36.8 million (2020), against an average of $39.6 million.
  • The largest annual shift saw Accumulated Depreciation grew 8.8% in 2020 before it fell 9.24% in 2021.
  • A 3-year view of Accumulated Depreciation shows it stood at $36.8 million in 2020, then decreased by 9.24% to $33.4 million in 2021, then skyrocketed by 45.49% to $48.6 million in 2024.
  • Per Business Quant, the three most recent readings for STRO's Accumulated Depreciation are $48.6 million (Q4 2024), $33.4 million (Q4 2021), and $36.8 million (Q4 2020).